GMO US Quality ETF

QLTY

Market cap $2.92B

Each month brings new ETFs to the ever-expanding ETF ecosystem. And October had its fair share of intriguing launches.

On the latest ETF 360, VettaFi's Cinthia Murphy interviewed GMO Asset Allocation's Asset Allocation Strategist Catherine LeGraw. The two discussed quality, the speculative market, and value dislocation.

On Tuesday, GMO launched three new active ETFs. They are the GMO International Quality ETF (QLTI), the GMO U.S. Value ETF (GMOV), and the GMO International Value ETF (GMOI).

BOSTON--(BUSINESS WIRE)--GMO expands ETF offerings with the launch of GMO International Quality (QLTI), GMO U.S. Value (GMOV), and GMO International Value (GMOI).

BOSTON--(BUSINESS WIRE)---- $QLTY--GMO, a global investment manager, today announced that the GMO U.S. Quality ETF (NYSE: QLTY), has surpassed $1 billion in assets under management since launching in November 2023. “Reaching $1 billion less than one year after the launch of QLTY illustrates that clients are seeking quality amid rising uncertainties and questions about valuation in some parts of the market. GMO is committed to offering innovative investment solutions in the structures that best address th.

The GMO U.S. Quality ETF is designed to generate total return by investing in high-quality U.S. equities. One thing that stands out about the top 10 holdings of QLTY is Nvidia is nowhere to be found. The real differentiator is Healthcare, which has a more than double weighting relative to the S&P 500.

GMO's first exchange-traded fund is beating the S&P 500 so far in 2024 — without holding the skyrocketing stock of artificial-intelligence darling Nvidia Corp.

Firms should offer ETF products because investor demand is not slowing down, according to one Goldman Sachs ETF expert.

Redefining "active" investing... and how it comes to market.

The U.S. stocks appear expensive after investor mania surrounding artificial-intelligence interrupted the bursting of an initial market bubble that was deflating in 2022, according to GMO's Jeremy Grantham.